Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Sangamo Therapeutics stock | $8.32

Learn how to easily invest in Sangamo Therapeutics stock.

Sangamo Therapeutics Inc is a biotechnology business based in the US. Sangamo Therapeutics shares (SGMO) are listed on the NASDAQ and all prices are listed in US Dollars. Sangamo Therapeutics employs 413 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Sangamo Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SGMO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Sangamo Therapeutics stock price (NASDAQ: SGMO)

Use our graph to track the performance of SGMO stocks over time.

Sangamo Therapeutics shares at a glance

Information last updated 2021-10-23.
Latest market close$8.32
52-week range$8.13 - $19.43
50-day moving average $9.13
200-day moving average $10.35
Wall St. target price$20.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.95

Buy Sangamo Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sangamo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sangamo Therapeutics price performance over time

Historical closes compared with the close of $8.32 from 2021-10-22

1 week (2021-10-18) -2.69%
1 month (2021-09-24) -13.33%
3 months (2021-07-23) -16.30%
6 months (2021-04-23) -28.95%
1 year (2020-10-23) -23.25%
2 years (2019-10-24) -4.04%
3 years (2018-10-24) 12.35
5 years (2016-10-24) 121.87%

Sangamo Therapeutics financials

Revenue TTM $137.7 million
Gross profit TTM $-62,455,000
Return on assets TTM -10.27%
Return on equity TTM -28.29%
Profit margin -98.21%
Book value $3.07
Market capitalisation $1.2 billion

TTM: trailing 12 months

Shorting Sangamo Therapeutics shares

There are currently 10.5 million Sangamo Therapeutics shares held short by investors – that's known as Sangamo Therapeutics's "short interest". This figure is 2.2% down from 10.7 million last month.

There are a few different ways that this level of interest in shorting Sangamo Therapeutics shares can be evaluated.

Sangamo Therapeutics's "short interest ratio" (SIR)

Sangamo Therapeutics's "short interest ratio" (SIR) is the quantity of Sangamo Therapeutics shares currently shorted divided by the average quantity of Sangamo Therapeutics shares traded daily (recently around 958668.01099908). Sangamo Therapeutics's SIR currently stands at 10.91. In other words for every 100,000 Sangamo Therapeutics shares traded daily on the market, roughly 10910 shares are currently held short.

However Sangamo Therapeutics's short interest can also be evaluated against the total number of Sangamo Therapeutics shares, or, against the total number of tradable Sangamo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sangamo Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Sangamo Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0867% of the tradable shares (for every 100,000 tradable Sangamo Therapeutics shares, roughly 87 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Sangamo Therapeutics.

Find out more about how you can short Sangamo Therapeutics stock.

Sangamo Therapeutics share dividends

We're not expecting Sangamo Therapeutics to pay a dividend over the next 12 months.

Sangamo Therapeutics share price volatility

Over the last 12 months, Sangamo Therapeutics's shares have ranged in value from as little as $8.13 up to $19.43. A popular way to gauge a stock's volatility is its "beta".

SGMO.US volatility(beta: 1.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sangamo Therapeutics's is 1.6677. This would suggest that Sangamo Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sangamo Therapeutics overview

Sangamo Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.

Frequently asked questions

What percentage of Sangamo Therapeutics is owned by insiders or institutions?
Currently 17.206% of Sangamo Therapeutics shares are held by insiders and 53.808% by institutions.
How many people work for Sangamo Therapeutics?
Latest data suggests 413 work at Sangamo Therapeutics.
When does the fiscal year end for Sangamo Therapeutics?
Sangamo Therapeutics's fiscal year ends in December.
Where is Sangamo Therapeutics based?
Sangamo Therapeutics's address is: 7000 Marina Boulevard, Brisbane, CA, United States, 94005
What is Sangamo Therapeutics's ISIN number?
Sangamo Therapeutics's international securities identification number is: US8006771062
What is Sangamo Therapeutics's CUSIP number?
Sangamo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 800677106

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site